194 related articles for article (PubMed ID: 15234383)
1. [Clinical effectiveness of seven-valent pneumococcal conjugate vaccine (Prevenar) against invasive pneumococcal diseases: prospects for children in France].
Black S; Shinefield H; Cohen R; Floret D; Gaudelus J; Olivier C; Reinert P
Arch Pediatr; 2004 Jul; 11(7):843-53. PubMed ID: 15234383
[TBL] [Abstract][Full Text] [Related]
2. 7-valent pneumococcal conjugate vaccine: new preparation. Prevents rare invasive infections in infants.
Prescrire Int; 2002 Feb; 11(57):7-10. PubMed ID: 11985376
[TBL] [Abstract][Full Text] [Related]
3. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine.
Albrich WC; Baughman W; Schmotzer B; Farley MM
Clin Infect Dis; 2007 Jun; 44(12):1569-76. PubMed ID: 17516400
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
5. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
[TBL] [Abstract][Full Text] [Related]
6. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine.
Muñoz-Almagro C; Jordan I; Gene A; Latorre C; Garcia-Garcia JJ; Pallares R
Clin Infect Dis; 2008 Jan; 46(2):174-82. PubMed ID: 18171247
[TBL] [Abstract][Full Text] [Related]
7. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
[TBL] [Abstract][Full Text] [Related]
8. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases.
Rendi-Wagner P; Paulke-Korinek M; Kundi M; Burgmann H; Georgopoulos A; Vécsei A; Kollaritsch H
Vaccine; 2009 Jun; 27(30):3963-8. PubMed ID: 19393711
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
10. [Pneumococcal meningitis in children in France: 832 cases from 2001 to 2007].
Levy C; Varon E; Bingen E; Picard C; de La Rocque F; Aujard Y; Cohen R;
Arch Pediatr; 2008 Dec; 15 Suppl 3():S111-8. PubMed ID: 19268240
[TBL] [Abstract][Full Text] [Related]
11. Prevenar vaccination: review of the global data, 2006.
Center KJ
Vaccine; 2007 Apr; 25(16):3085-9. PubMed ID: 17287048
[TBL] [Abstract][Full Text] [Related]
12. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
13. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction--eight states, 1998-2005.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Feb; 57(6):144-8. PubMed ID: 18272956
[TBL] [Abstract][Full Text] [Related]
14. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006.
Motlova J; Benes C; Kriz P
Epidemiol Infect; 2009 Apr; 137(4):562-9. PubMed ID: 18796171
[TBL] [Abstract][Full Text] [Related]
15. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation.
Ispahani P; Slack RC; Donald FE; Weston VC; Rutter N
Arch Dis Child; 2004 Aug; 89(8):757-62. PubMed ID: 15269078
[TBL] [Abstract][Full Text] [Related]
16. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine.
Dias R; Caniça M
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):35-42. PubMed ID: 17854472
[TBL] [Abstract][Full Text] [Related]
17. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine.
Lacapa R; Bliss SJ; Larzelere-Hinton F; Eagle KJ; McGinty DJ; Parkinson AJ; Santosham M; Craig MJ; O'Brien KL
Clin Infect Dis; 2008 Aug; 47(4):476-84. PubMed ID: 18627249
[TBL] [Abstract][Full Text] [Related]
18. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
Siber GR; Chang I; Baker S; Fernsten P; O'Brien KL; Santosham M; Klugman KP; Madhi SA; Paradiso P; Kohberger R
Vaccine; 2007 May; 25(19):3816-26. PubMed ID: 17368878
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
[TBL] [Abstract][Full Text] [Related]
20. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Sep; 54(36):893-7. PubMed ID: 16163262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
